Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Microbix Secures Funded Drug Commercialization Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Microbix Biosystems

    Menu

    Microbix Biosystems

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Microbix Biosystems

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Microbix Secures Funded Drug Commercialization Agreement

              Details:

              The Agreement provides for Sequel to fund and undertake the necessary work to return Kinlytic (urokinase), a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture, to the U.S. for the clinical indication of venous catheter clearance.

              Lead Product(s): Urokinase

              Therapeutic Area: Hematology Product Name: Kinlytic

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sequel Pharma

              Deal Size: $35.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement May 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY